Intimation of receipt of request applications from promoters for reclassification in accordanxce with Reg. 31A of SEBI (LODR) Regulations, 2015
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Oxygenta Pharmaceutical Ltd has received reclassification requests from four outgoing promoters — all members of the Vankineni family — who want to move from the 'Promoter' category to the 'Public' category under SEBI LODR Regulation 31A. The four individuals collectively hold 9,42,700 equity shares, or about 2.55% of the company's share capital (Snigdha Vankineni 1.47%, Sumanth Simha Vankineni 0.93%, Sai Sudhakar Vankineni 0.08%, Jhansi Rani Vankineni 0.07%). No shares are being sold; this is purely a change in classification status. Each applicant has stated they are not involved in the company's management, are not board directors, and have no special rights or control over the company. The reclassification is subject to regulatory approval and compliance with SEBI's conditions over a minimum three-year period.
This move reduces the promoter group's shareholding by 2.55%, marginally expanding the public float. Since no shares are actually being sold, there is no direct impact on stock price or ownership value. The change mainly improves the accuracy of shareholding classification and may slightly improve the stock's free-float metrics.